L
Lazerwith Scott E
Researcher at Pfizer
Publications - 36
Citations - 1248
Lazerwith Scott E is an academic researcher from Pfizer. The author has contributed to research in topics: Fatty acid amide hydrolase & Integrase. The author has an hindex of 13, co-authored 36 publications receiving 1144 citations.
Papers
More filters
Journal ArticleDOI
Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Kay Ahn,Douglas S. Johnson,Mauro Mileni,David Beidler,Jonathan Z. Long,Michele K. McKinney,Eranthie Weerapana,Nalini Sadagopan,Marya Liimatta,Sarah E. Smith,Lazerwith Scott E,Cory Michael Stiff,Satwik Kamtekar,Keshab Bhattacharya,Yanhua Zhang,Stephen Swaney,Keri Van Becelaere,Raymond C. Stevens,Benjamin F. Cravatt +18 more
TL;DR: Mechanistic and structural studies confirm that PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile, and designate PF- 3845 as a valuable pharmacological tool for in vivo characterization of the endocannabinoid system.
Journal ArticleDOI
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
Manuel Tsiang,Gregg S. Jones,Joshua Goldsmith,Andrew Mulato,Derek Hansen,Elaine Kan,Luong Tsai,Rujuta A. Bam,George Stepan,Kirsten M. Stray,Anita Niedziela-Majka,Stephen R. Yant,Helen Yu,George Kukolj,Tomas Cihlar,Lazerwith Scott E,Kirsten L. White,Haolun Jin +17 more
TL;DR: The overall virologic profile of BIC supports its ongoing clinical investigation in combination with other antiretroviral agents for both treatment-naive and -experienced HIV-infected patients.
Journal ArticleDOI
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
Douglas S. Johnson,Cory Michael Stiff,Lazerwith Scott E,Suzanne Ross Kesten,Lorraine Kathleen Fay,Mark Morris,David Beidler,Marya Liimatta,Sarah E. Smith,David T. Dudley,Nalini Sadagopan,Shobha N. Bhattachar,Stephen J. Kesten,Tyzoon K. Nomanbhoy,Benjamin F. Cravatt,Kay Ahn +15 more
TL;DR: Compound 23 has exquisite selectivity for FAAH relative to other members of the serine hydrolase superfamily as demonstrated by competitive activity-based protein profiling and is being evaluated in human clinical trials.
Patent
Polycyclic carbamoylpyridone compounds and their pharmaceutical use
Bacon Elizabeth M,Zhenhong R. Cai,Cottell Jeromy J,Mingzhe Ji,Haolun Jin,Lazerwith Scott E,Morganelli Philip Anthony,Hyung-Jung Pyun +7 more
TL;DR: In this paper, the authors have proposed a set of compounds for use in the treatment of human immunodeficiency virus (HIV) infection, including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, Y1, Y2, or L are as defined herein.
Journal ArticleDOI
Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).
Douglas S. Johnson,Kay Ahn,Suzanne Ross Kesten,Lazerwith Scott E,Yuntao Song,Mark Morris,Lorraine Kathleen Fay,Tracy Fay Gregory,Cory Michael Stiff,James B. Dunbar,Marya Liimatta,David Beidler,Sarah E. Smith,Tyzoon K. Nomanbhoy,Benjamin F. Cravatt +14 more
TL;DR: The synthesis and structure-activity relationships (SAR) of a series of benzothiophene piperazine and piperidine urea FAAH inhibitors is described, and several compounds showed in vivo activity in a rat complete Freund's adjuvant model of inflammatory pain.